


CL2A-SN-38

| | |
|---------------------------|--|
| Cat. No.: | HY-128946 |
| CAS No.: | 1279680-68-0 |
| Molecular Formula: | C ₇₃ H ₉₇ N ₁₁ O ₂₂ |
| Molecular Weight: | 1480.61 |
| Target: | Drug-Linker Conjugates for ADC |
| Pathway: | Antibody-drug Conjugate/ADC Related |
| Storage: | -20°C, stored under nitrogen * In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen) |



SOLVENT & SOLUBILITY

| | | | | | |
|---|--|--------------------------|-----------|-----------|-----------|
| In Vitro | DMSO : 100 mg/mL (67.54 mM; Need ultrasonic) | | | | |
| | | Solvent Concentration | Mass | | |
| | Preparing Stock Solutions | | 1 mg | 5 mg | 10 mg |
| | | 1 mM | 0.6754 mL | 3.3770 mL | 6.7540 mL |
| | | 5 mM | 0.1351 mL | 0.6754 mL | 1.3508 mL |
| | 10 mM | 0.0675 mL | 0.3377 mL | 0.6754 mL | |
| Please refer to the solubility information to select the appropriate solvent. | | | | | |
| In Vivo | 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: 2.08 mg/mL (1.40 mM); Clear solution; Need ultrasonic | | | | |
| | 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.08 mg/mL (1.40 mM); Clear solution | | | | |
| | 3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (1.40 mM); Clear solution | | | | |

BIOLOGICAL ACTIVITY

| | |
|-------------------------------------|---|
| Description | CL2A-SN-38 is a agent-linker conjugate composed of a potent a DNA Topoisomerase I inhibitor SN-38 and a linker CL2A to make antibody agent conjugate (ADC). CL2A-SN-38 provides significant and specific antitumor effects against a range of human solid tumor types. CL2A-SN-38 uses hydrolyzable linker to deliver active agents within tumor cells and in the tumor microenvironment, resulting in bystander effects ^[1] . |
| IC₅₀ & Target | Camptothecins |
| In Vivo | CL2A-SN-38 coupled to the anti-Trop-2 humanized antibody hRS7 (intraperitoneal injection, 0.2 or 0.4 mg/kg, twice weekly, 4 weeks) can both significantly inhibit tumor growth in mice with human colon (COLO 205) or pancreatic (Capan-1) tumour |

xenografts^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- AAPS J. 2022 May 27;24(4):70.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Thomas M Cardillo, et al. Humanized anti-Trop-2 IgG-SN-38 conjugate for effective treatment of diverse epithelial cancers: preclinical studies in human cancer xenograft models and monkeys. Clin Cancer Res. 2011 May 15;17(10):3157-69.

[2]. Cardillo TM, et al. Humanized anti-Trop-2 IgG-SN-38 conjugate for effective treatment of diverse epithelial cancers: preclinical studies in human cancer xenograft models and monkeys. Clin Cancer Res. 2011 May 15;17(10):3157-69.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA